Composition
Each 5 ml syrup contains Butamirate Citrate INN 7.5 mg.
Pharmacology
Mita (Butamirate Citrate) acts directly on the brain’s cough center to suppress cough. In addition to its antitussive effect, Mita also decreases the airway resistance. It is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. Mita is rapidly and completely absorbed after oral administration. Mita is extremely protein bound and plasma elimination half-life is about 13 hours.
Indication
Mita (Butamirate Citrate) is used to relieve dry (non-productive) cough. Mita is indicated in acute cough of any etiology, pre and post-operative cough sedation for surgical procedure and bronchoscopy. It can be used in acute cough of any etiology, whooping cough and cough due to acute lower respiratory tract infections (tracheitis, laryngitis, bronchitis) etc.
Dosage & Administration
| Dosage Form | Age | Dose |
| Mita Syrup | Children (3-6 years) | 5 ml 3 times daily |
| Children (6-12 years) | 10 ml 3 times daily | |
| Adolescent | 15 ml 3 times daily | |
| Adult | 15 ml 4 times daily |
Contraindication
Butamirate Citrate is contraindicated in patients with known hypersensitivity to any compound of the formulation.
Warning and Precaution
Due to inhibition of the cough reflex by Butamirate Citrate, the simultaneous administration of expectorants has to be avoided, because it may lead to the stagnation of mucus in the respiratory tract, which increases the risk of bronchospasm and airways infection. A doctor or pharmacist needs to be consulted if the cough persists for more than 7 days.
Side Effects
Tolerance of Butamirate Citrate is good. Adverse reactions such as rash, nausea and vertigo have been observed in a few rare cases, resolving after dose reduction or treatment withdrawal.
Use in Pregnancy and Lactation
Butamirate Citrate should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Butamirate Citrate administration during lactation should be carefully weighed against the risks.
Use in Children and Adolescents
Mita can be given to 3 years children and it is safe for adolescents.
Drug Interaction
Concomitant use of expectorants may lead to retention of mucous in the respiratory system, which can increase the risk of bronchospasm and airway infection.
Overdose
Accidental overdose with Butamirate Citrate can cause the following symptoms: drowsiness, nausea, vomiting, diarrhoea, loss of balance and hypertension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.
Storage
Store below 30°C, protect from light and moisture. Keep out of the reach of children.
Packaging
Each PET bottle contains 100 ml syrup with a measuring cup.
